Comparison
Bremelanotide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
189691-06-3
2179963-22-7
Molecular weight
1025.18 g/mol
4727 g/mol
Half-life
2.7 h
168 h
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
5
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
2